AstraZeneca Highlights Significant Gains Across Three Major Cancer Trials At ASCO
AstraZeneca Plc (NASDAQ:AZN) on Monday released results from three Phase 3 clinical trials at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting: DESTINY-Breast09, MATTERHORN, and SERENA-6.
In the DESTINY-Breast09 trial, Enhertu (trastuzumab deruxtecan) combined with pertuzumab was evaluated as a first-line treatment for HER2-positive metastatic breast cancer, compared to a standard regimen of a taxane, trastuzumab, and pertuzumab (THP).
Topline data were shared in April.Results indicated that the Enhertu combination reduced the risk of disease progression or death by 44%. Median progression-free survival (PFS) reached 40.7 months with the Enhertu regimen versus 26.9 months for THP, a benefit observed across patient subgroups.
Investigator-assessed median PFS was 40.7 months for the Enhertu arm and 20.7 months for THP. The confirmed objective response rate was 85.1% for the Enhertu combination and 78.6% for THP, with 58 complete responses in the Enhertu group compared to 33 with THP.
The median duration of response was 39.2 months for the Enhertu combination and 26.4 months for THP. Overall survival data was not yet mature, though an early trend favored the Enhertu combination.
The MATTERHORN trial assessed Imfinzi (durvalumab) with standard FLOT chemotherapy as a perioperative treatment for resectable, early-stage, and locally advanced gastric and gastroesophageal junction (GEJ) cancers, compared to chemotherapy alone.
Topline data were released in March.
A planned interim analysis showed that the Imfinzi-based regimen led to a 29% reduction in the risk of disease progression, recurrence, or death.
Median event-free survival (EFS) was not reached in the Imfinzi arm, compared to 32.8 months in the chemotherapy-alone arm. The estimated 24-month EFS rate was 67.4% for the Imfinzi regimen and 58.5% for chemotherapy alone.
A trend towards improved overall survival was noted for the Imfinzi-based regimen, with formal assessment to follow.
The SERENA-6 trial investigated camizestrant combined with a cyclin-dependent kinase (CDK) 4/6 inhibitor (palbociclib, ribociclib or abemaciclib) in patients with hormone receptor (HR)-positive, HER2-negative advanced breast cancer whose tumors developed an ESR1 mutation during first-line treatment with an aromatase inhibitor (AI) and a CDK4/6 inhibitor.
Topline data were shared in February.
The trial compared switching to the camizestrant combination against continuing the AI plus CDK4/6 inhibitor. The camizestrant combination reduced the risk of disease progression or death by 56%.
Median PFS was 16.0 months for patients who switched, versus 9.2 months for those continuing the AI combination. The median time to deterioration of global health status was 23.0 months for the camizestrant arm and 6.4 months for the AI combination arm.
While data for time to second disease progression and overall survival were immature, a trend favored the camizestrant combination for PFS2.
Price Action: AZN stock is trading lower by 0.95% at $72.14 at last checkMonday.
Read Next:Photo by Piotr Swat Shutterstock
UNLOCKED: 5 NEW TRADES EVERY WEEK. Click now to get top trade ideas daily, plus unlimited access to cutting-edge tools and strategies to gain an edge in the markets.
Get the latest stock analysis from Benzinga?
ASTRAZENECA (AZN): Free Stock Analysis Report
This article AstraZeneca Highlights Significant Gains Across Three Major Cancer Trials At ASCO originally appeared on Benzinga.com
© 2025 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Medscape
2 days ago
- Medscape
ASCO 2025: New Standards Reshape Care in mBC
Heather McArthur, MD, describes how the 2025 ASCO Annual Meeting brought exciting advances in the metastatic breast cancer space. In PD-L1-positive triple-negative breast cancer, sacituzumab govitecan combined with pembrolizumab significantly improved progression-free survival over standard chemotherapy plus pembrolizumab, quickly becoming a new standard of care. Similarly, in HER2-positive disease, trastuzumab deruxtecan combined with pertuzumab outperformed traditional THP therapy, offering a new frontline option. Overall, these findings signify a major shift in how to treat metastatic breast cancer.
Yahoo
2 days ago
- Yahoo
Transgene completes initial screening in Phase II part of TG4050 vaccine trial
Transgene has completed the initial subject screening for the Phase II segment of its Phase I/II trial of individualised neoantigen therapeutic vaccine, TG4050, as a monotherapy in the adjuvant treatment of human papillomavirus (HPV)-negative squamous head and neck cancers. The vaccine is based on the myvac platform powered by its partner NEC's AI to enhance antigen selection. During the Phase I portion of the trial, all subjects treated with the vaccine remained disease-free post a minimum follow-up of two years, demonstrating clinical proof of principle. Translational data indicated that these subjects showed sustained T cell responses at 24 months. Meeting all trial endpoints, the findings were shared at the American Society of Clinical Oncology (ASCO 2025) annual meeting. The company anticipates completing the randomisation of all subjects in the Phase II part by the end of this year, after a second screening carried out post-surgery and adjuvant radiotherapy. Around 80 subjects who have completely responded to adjuvant therapy are expected to be enrolled and randomised in the Phase I/II trial. The first immunogenicity data from the Phase II part are projected to be available in the second half of 2026, with preliminary efficacy data anticipated in the second half of 2027. The trial is assessing the treatment benefits of the vaccine in individuals at risk of relapse. So far, 32 evaluable patients have been included in the Phase I part, with the Phase II continuing globally. Transgene chief medical officer Dr Emmanuelle Dochy said: 'Timely completion of first patient screening of the Phase II part of our Phase I/II trial is an important milestone for Transgene and brings us one step closer to providing a new treatment option for patients living with operable squamous head and neck cancer. 'With meaningful data readouts expected over the next two years, we are preparing to deliver important data for TG4050 and, at the same time, explore its wider potential. We are grateful to the patients, their families, investigators, and clinical staff whose commitment made this achievement possible.' "Transgene completes initial screening in Phase II part of TG4050 vaccine trial" was originally created and published by Clinical Trials Arena, a GlobalData owned brand. The information on this site has been included in good faith for general informational purposes only. It is not intended to amount to advice on which you should rely, and we give no representation, warranty or guarantee, whether express or implied as to its accuracy or completeness. You must obtain professional or specialist advice before taking, or refraining from, any action on the basis of the content on our site. Sign in to access your portfolio
Medscape
2 days ago
- Medscape
Sexual Effects Persist After Cervical Cancer Treatment
CHICAGO — Patients treated for cervical cancer need dedicated survivorship care to address long-term symptoms and sexual health concerns. That was the conclusion of a review of patient-reported outcomes (PROs) from among 919 women in the international phase 3 OUTBACK trial. The PROs showed that numerous sexual health symptoms and concerns persist 3 years following treatment, Linda Mileshkin, MD, reported at the American Society of Clinical Oncology (ASCO) 2025. The 10 top-ranked PROs at 1-year follow-up — based on responses from the 64% of trial participants who completed a European Organisation for Research and Treatment of Cancer (EORTC) questionnaire — and their persistence or resolution at 2-3 years, based on responses from 37% of trial participants, are listed in the table below. Table. Frequency and Duration of Top-Ranked Moderate-to-Severe Symptoms 10 most common moderate-to-severe PROs after cervical cancer treatment Number (percentage) of patients reporting symptoms at 1 year Number (percentage) of patients reporting symptoms at year 2 or 3 Worries about future health 135 (44) 49 (36) Hot flashes/sweats 132 (37) 49 (37) Frequent urination 126 (35) 45 (36) Sexual activity not enjoyable 125 (64) 43 (34) Trouble sleeping 117 (32) 37 (32) Feeling tired 104 (29) 33 (32) Changes in bowel habits 102 (28) 41 (40) Financial difficulties 101 (28) 32 (32) Pain 96 (27) 23 (24) Dissatisfied with body 95 (26) 27 (28) PROs = patient-reported outcomes PROs were based on responses to the EORTC core questionnaire QLQ-C30; cervical cancer module QLQ-CX24 (questions 50-54 only for sexually active points); EORTC Item Library questions on abdominal, urinary, bowel, and chemotherapy side effects; and FACT-GOG-NTX-4 neurotoxicity over 36 months. A moderate-to-severe long-term symptom issue was defined as a score in the worst 2 response categories (EORTC items), a total score ≤ 8/16 on FACT-GOG-NTX4 at years 1, 2, or 3 for Objectives 1-2, or an equivalent subscale score for Objective 3. Adapted from Mileshkin L. Program and abstracts of the 2025 ASCO Annual Meeting; May 30 to June 3, 2025; Chicago, Illinois. Abstract 5503. The OUTBACK trial assessed the addition of adjuvant chemotherapy (ACT) after chemoradiotherapy (CRT) for the treatment of locally advanced cervical cancer. That study demonstrated that ACT increased adverse events without improving overall survival compared with CRT alone. Regardless of whether patients were assigned to the CRT + ACT or CRT-only treatment group, the issues and frequencies from PROs in the current analysis were observed, reported Mileshkin, who is director of Medical Oncology at the Peter MacCallum Cancer Centre in Melbourne, Australia, and first author for the OUTBACK trial. Given the low questionnaire completion rates at 2-3 years, the PROs may represent underestimates, she said. At 1 year, moderate-to-severe peripheral neuropathy affected 24% and 18% of those who received CRT + ACT and those who received only CRT, respectively, and at 3 years, the corresponding rates were 19% and 12%. At baseline, 77% of patients reported no sexual activity in the prior 4 weeks, and at years 1, 2, or 3, 92% reported low sexual activity, 68% reported low enjoyment, 40% reported moderate-to-severe vaginal tightness, 37% reported vaginal dryness during sex, and 32% were moderately to severely worried that sex would be painful. The rates of poor sexual enjoyment were somewhat lower with CRT-only treatment, whereas the rates of sexual worry were higher among those with CRT + ACT. Age younger than 60 years was an independent risk factor for experiencing sexual concerns. Though limited by the low completion rate at 3 years and a lack of data on menopausal symptom management and use of vaginal estrogen or dilators, the findings underscored the importance of discussing and managing the long-term effects of CRT with patients, Mileshkin said during her presentation at the meeting. Cervical cancer treatment in clinical practice will change over time, but 'meanwhile, there's going to be hundreds of thousands of women who've had this type of treatment who continue to recover and live with these side effects,' she stressed. 'I hope [these findings] will help clinicians remember to ask patients about these issues and try to address them because women won't necessarily volunteer them themselves.' Mileshkin disclosed honoraria from GlaxoSmithKline and the limbic; research funding from BeiGene; and travel, accommodations, expenses, and another relationship with Roche.
